APOB and metabolic syndrome: While this suggests the target has not been met, the current Canadian guidelines recommend that, in the presence of more severe baseline dyslipidemia or in patients whom therapy is limited by drug intolerance (statins were contraindicated in 0.5% of patients), a 50% or greater reduction of LDL-C from baseline is recommended, or to consider apoB.